This paper is in the following e-collection/theme issue:

Patient-Reported Outcome Measures (PROMs) (288) Electronic/Mobile Data Capture, Internet-based Survey & Research Methodology (832) Research Instruments, Questionnaires, and Tools (576) Health Services Research (482)

Published on in Vol 22, No 3 (2020): March

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/17921, first published .
The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study

The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study

The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study

Authors of this article:

Nils-Henning Ness1 Author Orcid Image ;   Rocco Haase1 Author Orcid Image ;   Raimar Kern2 Author Orcid Image ;   Dirk Schriefer1 Author Orcid Image ;   Benjamin Ettle3 Author Orcid Image ;   Christian Cornelissen4 Author Orcid Image ;   Katja Akguen1 Author Orcid Image ;   Tjalf Ziemssen1 Author Orcid Image
Article Authors Cited by (18) Tweetations (6) Metrics

Journals

  1. Ness N, Schriefer D, Haase R, Ettle B, Ziemssen T. Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis. PharmacoEconomics 2020;38(8):883 View
  2. Voigt I, Benedict M, Susky M, Scheplitz T, Frankowitz S, Kern R, Müller O, Schlieter H, Ziemssen T. A Digital Patient Portal for Patients With Multiple Sclerosis. Frontiers in Neurology 2020;11 View
  3. Schriefer D, Haase R, Ettle B, Ziemssen T. Patient‐ versus physician‐reported relapses in multiple sclerosis: insights from a large observational study. European Journal of Neurology 2020;27(12):2531 View
  4. Ziemssen T, Hoffmann O, Klotz L, Schreiber H, Weber M, Rauser B. Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA. JMIR Research Protocols 2020;9(7):e19598 View
  5. Haase R, Schriefer D, Ziemssen T. Der Patient als Experte. DNP - Der Neurologe & Psychiater 2020;21(5):33 View
  6. Scholz M, Haase R, Schriefer D, Voigt I, Ziemssen T. Electronic Health Interventions in the Case of Multiple Sclerosis: From Theory to Practice. Brain Sciences 2021;11(2):180 View
  7. Schriefer D, Ness N, Haase R, Ziemssen T. Gender disparities in health resource utilization in patients with relapsing–remitting multiple sclerosis: a prospective longitudinal real-world study with more than 2000 patients. Therapeutic Advances in Neurological Disorders 2020;13 View
  8. Ness N, Schriefer D, Haase R, Ziemssen T. Der Multiple Sclerosis Health Resource Utilization Survey. Fortschritte der Neurologie · Psychiatrie 2022;90(01/02):42 View
  9. Poder T, Coulibaly L, Hassan A, Conombo B, Laberge M. Test–retest reliability of the Cost for Patients Questionnaire. International Journal of Technology Assessment in Health Care 2022;38(1) View
  10. Koeditz D, Frensch J, Bierbaum M, Ness N, Ettle B, Vudumula U, Gudala K, Adlard N, Tiwari S, Ziemssen T. Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany. Multiple Sclerosis Journal - Experimental, Translational and Clinical 2022;8(1) View
  11. Krüger K, Fricke L, Dilger E, Thiele A, Schaubert K, Hoekstra D, Heidenreich F, Brütt A, Stahmeyer J, Stahmann A, Röper A, Kubiak K, Hemmerling M, Grau A, Eichstädt K, Behrens S, Krauth C, Shen L. How is and how should healthcare for people with multiple sclerosis in Germany be designed?–The rationale and protocol for the mixed-methods study Multiple Sclerosis–Patient-Oriented Care in Lower Saxony (MS-PoV). PLOS ONE 2021;16(11):e0259855 View
  12. Koeditz D, Frensch J, Bierbaum M, Ness N, Ettle B, Ziemssen T. Evaluation der langfristigen klinischen und ökonomischen Auswirkungen einer Behandlung mit Ofatumumab gegenüber Dimethylfumarat und Glatirameracetat bei Patienten mit schubförmiger Multipler Sklerose aus gesellschaftlicher Sicht in Deutschland. Nervenheilkunde 2022;41(07/08):502 View
  13. Schriefer D, Haase R, Ness N, Ziemssen T. Cost of illness in multiple sclerosis by disease characteristics – A review of reviews. Expert Review of Pharmacoeconomics & Outcomes Research 2022;22(2):177 View
  14. Ziemssen T, Bhan V, Chataway J, Chitnis T, Campbell Cree B, Havrdova E, Kappos L, Labauge P, Miller A, Nakahara J, Oreja-Guevara C, Palace J, Singer B, Trojano M, Patil A, Rauser B, Hach T. Secondary Progressive Multiple Sclerosis. Neurology Neuroimmunology & Neuroinflammation 2023;10(1) View
  15. Ghiani M, Zhuleku E, Dillenseger A, Maywald U, Fuchs A, Wilke T, Ziemssen T. Data Resource Profile: The Multiple Sclerosis Documentation System 3D and AOK PLUS Linked Database (MSDS-AOK PLUS). Journal of Clinical Medicine 2023;12(4):1441 View
  16. Ziemssen T, Richter S, Mäurer M, Buttmann M, Kreusel B, Poehler A, Lampl M, Linker R. OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany. Frontiers in Neurology 2022;13 View
  17. Garfield K, Thorn J, Noble S, Husbands S, Hollingworth W. Development of a brief, generic, modular resource-use measure (ModRUM): piloting with patients. BMC Health Services Research 2023;23(1) View
  18. Brüggemann F, Gross S, Süße M, Hok P, Strauss S, Ziemssen T, Frahm N, Zettl U, Grothe M. Polypharmacy in patients with multiple sclerosis and the impact on levels of care and therapy units. Frontiers in Neurology 2023;14 View